-
1دورية أكاديمية
المؤلفون: Gerhard-Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J, Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben-Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, Rosenwald, Andreas
المصدر: Gerhard-Hartmann , E , Goergen , H , Bröckelmann , P J , Mottok , A , Steinmüller , T , Grund , J , Zamò , A , Ben-Neriah , S , Sasse , S , Borchmann , S , Fuchs , M , Borchmann , P , Reinke , S , Engert , A , Veldman , J , Diepstra , A , Klapper , W & Rosenwald , A 2022 , ' 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma : an analysis from the German Hodgkin ....
مصطلحات موضوعية: fluorescence in situ hybridisation, CD274, classical Hodgkin lymphoma, immune checkpoint blockade, major histocompatibility complex, SINGLE-ARM, PD-L1 IMMUNOHISTOCHEMISTRY, BRENTUXIMAB VEDOTIN, DIAGNOSTIC-TOOL, NIVOLUMAB, BLOCKADE, TRANSPLANTATION, MULTICOHORT, MULTICENTER, FAILURE
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1111/bjh.17793Test
https://hdl.handle.net/11370/ec6cf59f-7f4a-4fc1-976b-bd099f4d3d91Test
https://research.rug.nl/en/publications/ec6cf59f-7f4a-4fc1-976b-bd099f4d3d91Test
https://pure.rug.nl/ws/files/183281181/9p24.1_alterations_and_programmed_cell_death_1_ligand_1_expression_in_early_stage_unfavourable_classical_Hodgkin_lymphoma_an_analysis_from_the_German_Hodgkin_Study_Group_NIVAHL_trial.pdfTest -
2دورية أكاديمية
المؤلفون: Gerhard‐Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J., Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben‐Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, Rosenwald, Andreas
المصدر: British Journal of Haematology; Jan2022, Vol. 196 Issue 1, p116-126, 11p
مصطلحات موضوعية: PROGRAMMED death-ligand 1, HODGKIN'S disease, MANTLE cell lymphoma, MAJOR histocompatibility complex